Other mechanisms may include bFGF acting as a chemo-attractant that could be released, e.g., by reactive astrocytes following different pathological insults such as demyelination in MS or cortical injury (Rowntree and Kolb, 1997; Clemente et al., 2011). Here, FGF2 is linked to myeloid sarcoma.